Thanks, Len.
multiple its its across million me Let ability profile on retinal with begin injections. by leader based improve along established XX market to safety with vision diseases the EYLEA, over
addition vein AME occlusion the diabetic retinal was for macular the edema or macular EYLEA's following in for FDA of indication treatment and May involved based AMD label edema EYLEA include DME, to centrally In retinopathy diabetic expanded study. the or to without panorama for wet on
of demonstrated incidence In the complications. label updated to reduction an this in XX% diabetic XXX% setting EYLEA retinopathy shows vision-threatening that our
In on addition, action our for EYLEA filing syringe. awaiting the prefilled are resubmitted we FDA
clinical wet two to to In DME XX-week higher terms and of programs regimens recommended and are AMD disease, retinal our regimen future EYLEA dose in innovation aflibercept of in XX by end milligrams weeks. test the formulation eight doses studies a of initiate XXXX. with of compared we These higher of the every in planning will aflibercept in
therapy, preclinical our continuing blocker, VEGF other are at and development including collaborators of new we gene a approaches new novel Alnylam. aflibercept, with Beyond
benefitting patients and/or DUPIXENT, now that has many Breakthrough like diseases. I'd atopic of variety allergic to turn a Therapy our wide in to already
As mentioned, several achieved Len important regulatory milestones. we
CHMP Human anticipated from of XXXX. nasal the polyposis Medicinal end approvals, Beyond is for Use European with the highlighted an by the opinion rhinosinusitis by or for chronic Committee Products
of years atopic you to need this severe III population. unmet the dermatitis positive in trial we patients XX six intend And regulators I the to just morning aged of to like to this the submit in coming we pediatric would Phase months. remind results announced in tremendous which
of most their disease leaving lives body XX% had and our children devastated much hope. On the covered without and nearly with their suffered this had study and their average, of the for families lesions children from on
average by anxiety, of an and about children by the for Not skin only depression, families. also reduce life as both quality of it score of did dramatically health-related involvement and their measures DUPIXENT XX%, EASI improved measured
The skin confirmed numerically infections. established once safety study also profile reduced and again, DUPIXENT's
to are bringing patients interleukin-X DUPIXENT deeply to We the driven from of suffering interleukin-XX committed a range pathways. diseases inflammatory X team by Type and
disease mind, eosinophilic in goal the actively Phase that COPD. obstructive in or III in With we and enrolling patients are esophagitis pulmonary chronic studies
we DUPIXENT reminder, allergy a effectiveness the are as peanut settings allergy. such exploring in As and desensitization for grass also of
in study of of discontinued single to XX testing effective DUPIXENT only reactions reaction. DUPIXENT severe. therapy which subcutaneous course SCIT grass immunotherapy SCIT of IIa mostly the meaningful the when per with with trial completed We a success patients allergic combined that can SCIT or efficacy due because therapy this discontinued allergy showed in whether small for about The clinically can to patient many to who complete tolerability, recently safety, patients allergic preliminary be improve compared an about long-term, treatment be can't prolonged group, time due While patients immunotherapy reactions and for could required Phase XX a results and arm, the the allergy. allergic not
SCIT of there reduction tolerability future the looking with allergic analysis, combination. are meeting. efficacy therapy to of was we of in and the presenting symptoms forward or terms the DUPIXENT SCIT no the primary increase medical encouraged Thus to the in at results the difference we're potential And in of by a
XXXX made quarter, provide showing moderate-to-severe asthma. Regeneron an patients, our this secondary a antibody asthma XXXX, proof-of-concept may that Earlier in endpoints Regeneron that reported we interleukin-XX therapeutic primary in for alternative option and study
for the Although the Regeneron those XXXX DUPIXENT than lower calibrator results arm. were numerically
In not comparison. did increased of power in to the this combination not addition, Regeneron to and was XXXX monotherapy the DUPIXENT DUPIXENT benefit study although trial, this demonstrate compared
addition, dermatitis. results in and from XX interim months, X,XXX we're next In Phase Regeneron X the atopic the COPD in expecting studies
first efforts Last our squamous I to to EU PD-X cancer. approved with were in kind and advanced for cutaneous antibody Libtayo surgery only metastatic cell shift advanced with treat will curative gears U.S. approved or CSCC with candidates Starting radiation medicine now the or for locally carcinoma, making curative the Libtayo. any month, not immunotherapy patients for who in was of adults the Europe. our and
of available study in broader CSCC. patients, goal started CSCC making from Phase a adjuvant Libtayo X the we of population With
scheduled addition In our in neurological is study setting the the study, in start fourth ongoing to investigator-initiated an to quarter.
Additionally, our skin common cell most to carcinoma, Libtayo in the basal the pivotal year. is out study of half cancer next expected read of in first
in Moving on cell Phase enrollment to non-small expressors. by we PD-LX for pleased high Libtayo are the our trial X lung monotherapy cancer,
PD-LX which enrollment commenced X plus cancer lung regardless have two chemotherapy alone chemotherapy study, will status compare other Phase in or histology. We our to of Libtayo of part
we bind. bispecific broad two the customers under bispecific the In which are franchise on have checkpoint Beyond The bispecifics or the to of our investigational T-cell four now antibody CDX bispecifics. inhibition, total, categories CDXX receptor based molecule clinical investigation. consists
newest MUCXXxCDX the PSMAxCDXX. bispecific of and our Our notably was first CDXXxCDX, BCMAxCDX, addition co-stimulatory
candidates enter clinic and expected months years. Additional upcoming are in to the to
and we patients. efficacy out complete lymphoma higher. our patients B-cell In observed XXXX doses pretreated In four presented with seven June, safety heavily of bispecific. treated large show to XX lymphoma or we data diffused milligrams rate high response XXXX, continues DLBCL CDXXxCDX for updated Regeneron responses XXXX non-Hodgkin's Regeneron in Regeneron particular, or in
Phase Recruitment no lymphoma, non-Hodgkin's the four manageable X had a of for refractory subtypes. ongoing. for other trial achieved syndrome neurotoxicity The failed which to demonstrated enroll and to study relapsed multi-arm complete patients has of responses. or CAR-T pivotal therapy, two several date. including potentially lymphoma Notably, DLBCL, prior and now XXXX is disease-specific XXXX of lymphoma non-Hodgkin's Regeneron cohorts these with Regeneron tolerability discontinuations will follicular
Our bispecific BCMAxCDX plan multiple relapsed the of in patients. are ovarian refractory data by clinical present enrolling for BCMAxCDX are preliminary antibodies We actively cancer that end XXXX. platinum-resistant studies two MUCXXxCDX and other to or myeloma CDX for
ongoing tumor T as or co-stimulatory CDXX antigen which membrane the is PSMA co-stimulatory on first molecule Regeneron for recruitment as on binds Finally, well candidate cells. XXXX, prostate-specific the cells,
synergy immunotherapy immunotherapy up possibility Based could have a large patients we alone. If to this evidence, of our hoping see currently preclinical who that proven option. approach co-stims to successful, cancer, resistant not of disease prostate have with settings, this to number on in of as Libtayo such are open the do innovative
hemoglobinuria, familial data of study of a Fibrodysplasia our study Activin-A our osteoarthritis pivotal ANGPTL-X readout PNH. hypercholesterolemia, antibody studies expect also as end are FLP. end XXXX, readout as Phase disease Progressiva, nocturnal of planning In programs the enrolled our are data X the for other or are our of rare expected fasinumab, patients antibody or antibody By pipeline. we advanced CX candidate with our in for addition, of the well we emerging this related By XXXX. now present fully pain Phase and a X in homozygous during to expect paroxysmal we year, of updates to in number Ossificans
the Genetics celebrated just fifth with we have linking records. individuals sequenced anniversary we Regeneron exome of To Finally, XXX,XXX medical The their date, data Center. detailed
work a be about database We Biobank U.K. the here, collaboration ongoing leading of including continue consortium biopharma to our progress. to our excited in sequence with effort
Mining which are of diseases, of targets discovered Genetics already and/or Regeneron positively impacting development Center database had genetic efforts. across validated drug a clinical human number several The our
that, call Marion. now to over With turn I'll the
